| None (N=23763) |
Bupropion (N=10145) |
GLP Agonist (N=2851) |
Naltrexone (N=744) |
Orlistat (N=231) |
Sympathomimetic (N=1797) |
Overall (N=39531) |
|
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Male | 10668 (44.9%) | 3508 (34.6%) | 1080 (37.9%) | 406 (54.6%) | 52 (22.5%) | 240 (13.4%) | 15954 (40.4%) |
| Female | 13095 (55.1%) | 6637 (65.4%) | 1771 (62.1%) | 338 (45.4%) | 179 (77.5%) | 1557 (86.6%) | 23577 (59.6%) |
| Race | |||||||
| White | 12148 (51.1%) | 7377 (72.7%) | 1704 (59.8%) | 499 (67.1%) | 128 (55.4%) | 1144 (63.7%) | 23000 (58.2%) |
| Black | 6354 (26.7%) | 1565 (15.4%) | 615 (21.6%) | 130 (17.5%) | 59 (25.5%) | 345 (19.2%) | 9068 (22.9%) |
| Asian | 326 (1.4%) | 68 (0.7%) | 44 (1.5%) | 9 (1.2%) | 0 (0%) | 18 (1.0%) | 465 (1.2%) |
| Hispanic | 4262 (17.9%) | 850 (8.4%) | 404 (14.2%) | 85 (11.4%) | 34 (14.7%) | 225 (12.5%) | 5860 (14.8%) |
| Other | 673 (2.8%) | 285 (2.8%) | 84 (2.9%) | 21 (2.8%) | 10 (4.3%) | 65 (3.6%) | 1138 (2.9%) |
| Age (y) | |||||||
| Mean (SD) | 65.6 (12.5) | 58.8 (13.9) | 61.8 (12.6) | 56.4 (12.6) | 62.6 (13.4) | 54.5 (12.6) | 62.9 (13.4) |
| Median [Min, Max] | 67.0 [20.6, 91.3] | 60.4 [21.7, 91.0] | 63.0 [24.0, 90.5] | 58.1 [22.4, 86.3] | 63.8 [25.0, 90.1] | 54.6 [23.5, 86.9] | 64.3 [20.6, 91.3] |
| Diabetes | |||||||
| No Diabetes | 3425 (14.4%) | 6991 (68.9%) | 571 (20.0%) | 561 (75.4%) | 124 (53.7%) | 1344 (74.8%) | 13016 (32.9%) |
| Diabetes | 20338 (85.6%) | 3154 (31.1%) | 2280 (80.0%) | 183 (24.6%) | 107 (46.3%) | 453 (25.2%) | 26515 (67.1%) |
| Education Level | |||||||
| Less than a high school degree or equivalent | 2603 (11.0%) | 549 (5.4%) | 171 (6.0%) | 68 (9.1%) | 19 (8.2%) | 71 (4.0%) | 3481 (8.8%) |
| High School or GED | 5202 (21.9%) | 1848 (18.2%) | 516 (18.1%) | 180 (24.2%) | 57 (24.7%) | 287 (16.0%) | 8090 (20.5%) |
| College 1-3 years | 7418 (31.2%) | 3397 (33.5%) | 971 (34.1%) | 229 (30.8%) | 73 (31.6%) | 615 (34.2%) | 12703 (32.1%) |
| College graduate or advanced degree | 8540 (35.9%) | 4351 (42.9%) | 1193 (41.8%) | 267 (35.9%) | 82 (35.5%) | 824 (45.9%) | 15257 (38.6%) |
| Income | |||||||
| <$50k | 14519 (61.1%) | 5592 (55.1%) | 1538 (53.9%) | 470 (63.2%) | 143 (61.9%) | 822 (45.7%) | 23084 (58.4%) |
| $50k-$100k | 5305 (22.3%) | 2489 (24.5%) | 723 (25.4%) | 154 (20.7%) | 55 (23.8%) | 509 (28.3%) | 9235 (23.4%) |
| $100k-$150k | 2207 (9.3%) | 1150 (11.3%) | 330 (11.6%) | 65 (8.7%) | 18 (7.8%) | 253 (14.1%) | 4023 (10.2%) |
| $150k-$200k | 802 (3.4%) | 449 (4.4%) | 118 (4.1%) | 17 (2.3%) | 7 (3.0%) | 96 (5.3%) | 1489 (3.8%) |
| >$200k | 930 (3.9%) | 465 (4.6%) | 142 (5.0%) | 38 (5.1%) | 8 (3.5%) | 117 (6.5%) | 1700 (4.3%) |
| Glaucoma | |||||||
| No Glaucoma | 17734 (74.6%) | 9417 (92.8%) | 2700 (94.7%) | 706 (94.9%) | 208 (90.0%) | 1717 (95.5%) | 32482 (82.2%) |
| Glaucoma | 6029 (25.4%) | 728 (7.2%) | 151 (5.3%) | 38 (5.1%) | 23 (10.0%) | 80 (4.5%) | 7049 (17.8%) |